Clinical Competition Candidate

MYDAYIS

CNS · ADHD, adults (extended-release mixed amphetamine salts)

MYDAYIS carries product and use-code patents, low complexity (1/5), and meaningful clinical competition (4/5). The listed expiry window is approximately 38 months away. Active clinical competition may compress the generic entry window.

Back to watchlist Contact us about this drug

LOE window

38months

to latest listed patent expiry (August 24, 2029)

Expiry attractiveness: 4/5

Patent profile

Substance patent (none)

Product / formulation patent (listed)

Use-code patent (listed)

Patent count: 2

Complexity score: 1/5

Clinical competition

Score: 4/5

Active trials linked: 9

Phase 2/3 trials: 7

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

Applicant (NDA holder): TAKEDA PHARMACEUTICALS USA INC

Confidence: High

Market context

Therapeutic area: CNS

Indication: ADHD, adults (extended-release mixed amphetamine salts)

U.S. market size (est.)$100M – $500M

Estimated U.S. net sales tier. Verify current figures before commercial diligence.